Targets › CASR
3 programs from 3 companies in 7 trials: 5 Phase 3, 2 Phase 2; Genitourinary, Metabolic and endocrine; next expected readout Nov 2026.
G protein-coupled receptor that senses changes in the extracellular concentration of calcium ions and plays a key role in maintaining calcium homeostasis. Senses fluctuations in the circulating calcium concentration: activated by elevated circulating calcium, leading to decreased parathyroid hormone (PTH) secretion in parathyroid glands (By similarity). (UniProt, P41180)
Open in Phaseline: the race on CASR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Shaanxi Micot Pharmaceutical Technology | MT1013 Calcimimetic agent (allosteric modulator of calcium-sensing receptor) | CASR | Phase 3 | Secondary Hyperparathyroidism, Chronic Kidney Disease; Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis | Nov 2026 |
| Amgen | Etelcalcetide Calcium sensing receptor agonist | CASR | Phase 3 | Secondary Hyperparathyroidism | Jun 2027 |
| Calcilytix Therapeutics, Inc., a BridgeBio company | Encaleret Calcimimetic agent; allosteric activator of the calcium-sensing receptor (CaSR) | CASR | Phase 3 | Hypoparathyroidism; Autosomal Dominant Hypocalcemia (ADH); Autosomal Dominant Hypocalcemia Type 1 (ADH1) | Jan 2028 |
Secondary Hyperparathyroidism (2) Hypoparathyroidism (1) Autosomal Dominant Hypocalcemia (ADH) (1) Autosomal Dominant Hypocalcemia Type 1 (ADH1) (1) Secondary Hyperparathyroidism, Chronic Kidney Disease (1) Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis (1)
small molecule (2), protein or peptide (1)
Amgen (1) Calcilytix Therapeutics, Inc., a BridgeBio company (1) Shaanxi Micot Pharmaceutical Technology (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.